Company Encyclopedia
View More
name
Sol-Gel Tech
SLGL.US
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc.
4.514 T
SLGL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking83/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-29.59%E
    • Profit Margin-47.37%E
    • Gross Margin-1332.75%E
  • Growth ScoreB
    • Revenue YoY62.04%A
    • Net Profit YoY6.10%C
    • Total Assets YoY-19.52%E
    • Net Assets YoY-25.00%E
  • Cash ScoreC
    • Cash Flow Margin-211.11%D
    • OCF YoY62.04%A
  • Operating ScoreC
    • Turnover0.49C
  • Debt ScoreB
    • Gearing Ratio24.75%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Owner Opaleye Management Inc Buys 6,864 ($257.6K) Of Sol-Gel Technologies Ltd [SLGL]

    Opaleye Management Inc Beneficial Owner of Sol-Gel Technologies Ltd [SLGL] filed a Form 4 on December 3, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/1/25-12/3/25TransactionPurchaseShares6,864Price$37.53Value$257,610Ending Holdings: 380,964 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    SLGL
    +2.31%
    Reuters·
    US
    SLGL
    +2.31%

    Sol-Gel Technologies (NASDAQ:SLGL) Issues Quarterly Earnings Results

    Sol-Gel Technologies reported a quarterly earnings per share of ($2.13), missing analysts' estimates of ($2.09). The company had a negative net margin of 14.25% and a negative return on equity of 11.80%. Revenue for the quarter was $0.40 million, exceeding the expected $0.30 million. Shares traded down 2.6% to $35.09. Analysts have given the stock a consensus rating of 'Hold' with a target price of $50.00.

    Market Beat·
    US
    SLGL
    +2.31%
    Market Beat·
    US
    SLGL
    +2.31%

    Sol-Gel Technologies (SLGL) to Release Quarterly Earnings on Friday

    Sol-Gel Technologies (NASDAQ:SLGL) will release its Q3 2025 earnings on Friday, November 21, before the market opens. Analysts expect earnings of ($2.09) per share and revenue of $0.30 million. The company previously reported $4.17 EPS for Q2 2025, surpassing estimates. Shares are trading at $35.07, with a market cap of $97.69 million. Analysts have mixed ratings, with a consensus target price of $50.00. Sol-Gel develops dermatological drugs, including Twyneo and Epsolay.

    Market Beat·
    US
    SLGL
    +2.31%
    Market Beat·
    US
    SLGL
    +2.31%

    Sol-Gel Technologies Announces Key Leadership and Auditor Appointments

    Sol-Gel Technologies announced the appointment of Kesselman & Kesselman as independent auditors for 2025 and re-elected Mr. Moshe Arkin as interim CEO starting January 1, 2026. These appointments aim to ensure leadership continuity and financial oversight, supporting the company's strategic direction in the dermatology sector. The latest analyst rating for SLGL stock is a Buy with a $50.00 price target, though financial challenges and lack of valuation appeal present uncertainties.

    Tip Ranks·
    US
    SLGL
    +2.31%
    Tip Ranks·
    US
    SLGL
    +2.31%

    Sol-Gel Technologies Announces 2025 Annual General Meeting

    Sol-Gel Technologies Ltd. has announced its 2025 annual general meeting on November 11, 2025, focusing on key agenda items such as appointing Kesselman & Kesselman as independent auditors, re-electing board members, and re-appointing Moshe Arkin as interim CEO. Shareholders will review the financial statements for the fiscal year ended December 31, 2024. The board recommends voting in favor of all proposals. Spark's analysis rates SLGL stock as Neutral, citing financial performance challenges and the need for strategic improvements.

    Tip Ranks·
    US
    SLGL
    +2.31%
    Tip Ranks·
    US
    SLGL
    +2.31%
    © 2025 Longbridge｜Disclaimer